Zhong G, Luo X, Li J, Liao Y, Gui G, Sheng J. MTRR rs1532268 polymorphism and gastric cancer risk: evidence from a meta-analysis.
J Int Med Res 2022;
50:3000605221097486. [PMID:
35579185 PMCID:
PMC9127855 DOI:
10.1177/03000605221097486]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 04/11/2022] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE
The methionine synthase reductase (MTRR) gene encodes the MTRR enzyme involved in the metabolic pathway of homocysteine. Several studies investigated the effect of the MTRR rs1532268 gene polymorphism on the risk of gastric cancer (GC), but the results have been inconsistent.
METHODS
We performed a comprehensive and systematic search of PubMed, Google Scholar, MEDLINE, Science Direct, Scopus, CNKI, and Web of Science. Five studies were included in this meta-analysis to determine whether MTRR rs1532268 polymorphism contributes to the risk of GC.
RESULTS
Pooled data indicated that the MTRR rs1532268 polymorphism significantly increased GC risk under the allele comparison model (odds ratio [OR] = 1.14, 95% confidence interval [CI] = 1.01-1.29) and dominant model (OR = 1.14, 95% CI = 1.00-1.30). In the analysis stratified by ethnicity, no relationship was found in Whites or Asians.
CONCLUSION
Our meta-analysis suggests a positive correlation between MTRR rs1532268 polymorphism and GC development.
Collapse